Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results

Full government funding covers the therapeutic study, which Valion says will preserve its capital while generating efficacy data.

Rhea-AI Summary

Valion Bio (NASDAQ:VBIO) announced that Entolimod will advance into a government-funded animal study testing survival after radiation exposure. The Armed Forces Radiobiology Research Institute will evaluate treatment for gastrointestinal acute radiation syndrome, a form of radiation injury affecting the gut, following previously announced positive safety results.

The study is fully funded by NIAID's Radiation and Nuclear Countermeasures Program through an interagency agreement. Mice will receive Entolimod or saline 24 hours after radiation exposure and undergo 30 days of monitoring. The primary endpoint is survival compared between groups. Top-line results are anticipated in early December, the company said.

4 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Entolimod will advance into therapeutic efficacy testing at AFRRI, evaluating survival after radiation exposure.
• Minor pointTherapeutic study is fully funded by NIAID's Radiation and Nuclear Countermeasures Program.
• Minor pointPreviously announced positive safety results preceded advancement to therapeutic testing.
• Minor point. Forward-looking: it has not happened yet and may not happen.Valion anticipates top-line results in early December.

Negative

• None.

News Explained

The planned efficacy study’s partial-body irradiation model shields roughly 2.5% of the animals’ bone marrow, helping researchers distinguish effects linked to gastrointestinal injury from those linked to marrow recovery.

Key Figures

Top-line results timing: Early December Bone marrow shielding: Roughly 2.5% of the animals' bone marrow Treatment timing: 24 hours after radiation exposure +1 more

Top-line results timing

Early December

Anticipated timing for the therapeutic study results

Bone marrow shielding

Roughly 2.5% of the animals' bone marrow

Partial-body irradiation model

Treatment timing

24 hours after radiation exposure

Single administration of Entolimod or saline control

Monitoring period

30 days

After treatment in the study

Historical Context

1 past event · Latest: Oct 28

1 event

1. Oct 28

   safety study results

   24h Move

   -13.2%

   AFRRI reported final safety data supporting the next Entolimod therapeutic-efficacy evaluation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gi-ars, partial-body irradiation, primary endpoint, animal rule, +2 more

6 terms

gi-ars medical

"a model designed to assess gastrointestinal acute radiation syndrome (GI-ARS)"

A severe form of acute radiation sickness that damages the lining of the stomach and intestines after high doses of ionizing radiation, causing pain, vomiting, diarrhea, dehydration and risk of fatal infection. Investors track GI-ARS because it drives demand for medical treatments, emergency countermeasures and government stockpiles; progress in effective therapies or regulatory clearances can create sizable markets and influence the valuation of biotech and defense contractors working on those solutions.

partial-body irradiation medical

"the upcoming study's partial-body irradiation model"

Radiation therapy that delivers ionizing radiation to a specific, limited part of the body rather than to the entire body; used to treat or shrink tumors in a targeted area or to condition a region before a procedure. It is planned so the radiation fields and doses concentrate on the intended tissues while reducing exposure to the rest of the body; the size of the treated field and the dose determine both therapeutic effect and the risk of local side effects.

primary endpoint medical

"The primary endpoint is survival"

The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.

animal rule regulatory

"evaluated in animal models under the U.S. Food and Drug Administration's Animal Rule"

A regulatory pathway that allows safety and effectiveness of drugs or vaccines to be judged primarily from well-controlled animal studies when human trials would be unethical or impossible, such as for treatments against rare, lethal exposures. It matters to investors because approval via this route can speed a product to market for urgent or niche needs but carries extra scientific and regulatory risk—think of it as accepting a high-quality dress rehearsal instead of a live show, with requirements for strong animal models and often additional post-approval obligations.

toll-like receptor 5 agonist medical

"Entolimod is a novel Toll-like Receptor 5 agonist"

A toll-like receptor 5 (TLR5) agonist is a drug or molecule that binds to and activates TLR5, a protein on certain immune cells that senses bacterial flagellin and triggers innate immune responses. Think of TLR5 as a doorbell on immune cells and an agonist as the button that rings it, prompting inflammation or immune activation; investors care because this mechanism is used in vaccines and cancer or infectious‑disease therapies and affects clinical effects, safety, and regulatory review.

nf-κb medical

"designed to activate NF-κB signaling pathways"

NF-κB is a protein complex inside cells that acts like a master switch for inflammation, immune responses and cell survival; when turned on it tells many genes to produce signals that promote immune activity, cell growth or protection from stress. Investors care because drugs or diagnostics that affect NF-κB can influence treatments for cancers, autoimmune disorders and inflammatory diseases, so changes in NF-κB activity can meaningfully alter a therapy’s potential market and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN ANTONIO, TX / ACCESS Newswire / October 30, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today announced that the Armed Forces Radiobiology Research Institute ("AFRRI") will be evaluating the therapeutic efficacy of Entolimod. This phase will evaluate whether treatment administered after radiation exposure improves survival in a model designed to assess gastrointestinal acute radiation syndrome ("GI-ARS").

The therapeutic study is fully funded by the National Institute of Allergy and Infectious Diseases ("NIAID")/Radiation and Nuclear Countermeasures Program ("RNCP") under an Interagency Agreement with the Uniformed Services University ("USU")/AFRRI. Top-line results are anticipated in early December.

The decision to advance the program to the therapeutic phase comes just days after Valion announced positive safety results. Achieving this milestone uniquely positions Valion Bio, potentially further strengthening its competitive position, commercial opportunities, and fundamental outlook.

"NIAID's decision to move into therapeutic efficacy testing at AFRRI gives Entolimod a clear next milestone following the positive safety findings," said Dean Zikria, Interim Chief Executive Officer of Valion Bio. "The central question is now whether treatment after radiation exposure can improve survival in a model designed to isolate gastrointestinal injury. This fully funded study provides an opportunity to evaluate that potential while preserving Valion's capital and generating critical efficacy data to guide Entolimod towards its next stage of development."

Evaluating Entolimod's Potential to Improve Survival Following Radiation Exposure

Entolimod is being developed as a potential medical countermeasure for both the hematopoietic (or bone marrow) and gastrointestinal ("GI") forms of acute radiation syndrome ("ARS"). By shielding roughly 2.5% of the animals' bone marrow, the upcoming study's partial-body irradiation model will enable researchers to differentiate between effects linked to the mitigation of gastrointestinal injury and those associated with recovery.

Mice will receive a single administration of either Entolimod or saline control 24 hours after radiation exposure and then will be monitored for 30 days. The primary endpoint is survival, with outcomes to be compared between the treatment and control groups.

"GI-ARS remains a critical challenge in the development of medical countermeasures," added Mr. Zikria. "Demonstrating a survival benefit in this model would underscore a novel and clinically significant milestone for Entolimod and further strengthen its potential role as a medical countermeasure for radiation emergencies. We would like to thank AFRRI and NIAID for their continued support and look forward to the results from this key study."

About Valion Bio, Inc.

Valion Bio, Inc. (NASDAQ:VBIO) is developing biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease and immune dysregulation.

The Company's lead candidate, Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome ("ARS") and has been evaluated in animal models under the U.S. Food and Drug Administration's ("FDA") Animal Rule, which allows the Agency to approve new drugs and biological products based on animal efficacy studies when human clinical trials are not ethical or feasible, such as in the case of acute radiation exposure. Entolimod is a novel Toll-like Receptor 5 agonist designed to activate NF-κB signaling pathways associated with cellular protection, tissue recovery and immune response. The product candidate has received Fast Track and Orphan Drug designations from the FDA. Valion holds an exclusive, worldwide license from Statera Biopharma to develop and commercialize Entolimod for ARS, radiation-induced neutropenia, and other indications.

Valion is also advancing Entolasta, a next-generation TLR5 agonist designed for potential use in broader therapeutic applications, including oncology supportive care. The Company's pipeline includes potential programs in neutropenia and immune dysfunction.

Valion's wholly owned subsidiary, Velocity Bioworks, is a biologics contract development and manufacturing organization providing development and manufacturing services to Valion to support its internal pipeline, with the objective of increasing manufacturing control, reducing costs, accelerating development timelines and strengthening domestic supply-chain security.

For more information, visit www.valionbio.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements in this press release include, among others, statements regarding: the timing and success of preclinical and clinical trials and study results, including the AFRRI/NIAID studies described herein; the development and regulatory advancement of Entolimod under the FDA Animal Rule; the timing and outcome of regulatory or government interactions;the initiation, design, timing and outcome of investigator-sponsored studies in neutropenia; the development and potential applications of Entolasta; the ability of the Company to expand the TLR5 platform into oncology supportive care or other indications; and the Company's ability to obtain additional capital and the continued listing of the Company's common stock on the Nasdaq Capital Market. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Valion's actual results to differ from those contained in the forward-looking statements, see Valion's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, under the heading "Risk Factors"; as well as the Company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Valion undertakes no duty to update such information except as required by applicable law.

Investor and Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@valionbio.com

SOURCE: Valion Bio, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Valion Bio's Entolimod therapeutic study measure?

The study's primary endpoint is survival, comparing mice receiving Entolimod with those receiving saline control. Each mouse will receive a single administration 24 hours after radiation exposure, followed by 30 days of monitoring.

When does Valion Bio expect results from the Entolimod therapeutic study?

Valion anticipates top-line results in early December. The study will evaluate whether Entolimod administered after radiation exposure improves survival in an animal model designed to assess gastrointestinal acute radiation syndrome.

Why will Valion Bio's Entolimod study shield some of the animals' bone marrow?

Shielding roughly 2.5% of the animals' bone marrow is intended to help researchers distinguish effects linked to mitigation of gastrointestinal injury from those associated with recovery. The study uses a partial-body irradiation model.